JPS589081B2 - ベヒクル組成物 - Google Patents

ベヒクル組成物

Info

Publication number: JPS589081B2
Authority: JP; Japan
Prior art keywords: composition; water; amount; wax; cream
Prior art date: 1973-04-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP49035716A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5058218A (fr

Inventor

マイケル・ジヨセフ・ブツセ

マイケル・ハロルド・フランクス

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Laboratories Ltd

Original Assignee

Glaxo Laboratories Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1973-04-02

Filing date

1974-04-01

Publication date

1983-02-18

1974-04-01 Application filed by Glaxo Laboratories Ltd filed Critical Glaxo Laboratories Ltd

1975-05-21 Publication of JPS5058218A publication Critical patent/JPS5058218A/ja

1983-02-18 Publication of JPS589081B2 publication Critical patent/JPS589081B2/ja

Status Expired legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 103
239000001993 wax Substances 0.000 claims description 33
239000006071 cream Substances 0.000 claims description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
239000002904 solvent Substances 0.000 claims description 22
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
150000003431 steroids Chemical class 0.000 claims description 10
239000008346 aqueous phase Substances 0.000 claims description 8
230000003110 anti-inflammatory effect Effects 0.000 claims description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
229940079593 drug Drugs 0.000 description 21
239000003814 drug Substances 0.000 description 21
239000004094 surface-active agent Substances 0.000 description 19
-1 And if desired Substances 0.000 description 18
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 14
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 13
238000002474 experimental method Methods 0.000 description 12
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
238000009472 formulation Methods 0.000 description 8
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
239000003921 oil Substances 0.000 description 8
229960002242 chlorocresol Drugs 0.000 description 7
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 7
239000004166 Lanolin Substances 0.000 description 6
229940039717 lanolin Drugs 0.000 description 6
235000019388 lanolin Nutrition 0.000 description 6
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
239000012071 phase Substances 0.000 description 6
235000013772 propylene glycol Nutrition 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 5
235000013871 bee wax Nutrition 0.000 description 5
239000012166 beeswax Substances 0.000 description 5
229940082500 cetostearyl alcohol Drugs 0.000 description 5
FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 5
229960002842 clobetasol Drugs 0.000 description 5
150000002191 fatty alcohols Chemical class 0.000 description 5
239000000314 lubricant Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
150000002334 glycols Chemical class 0.000 description 4
238000000034 method Methods 0.000 description 4
239000008213 purified water Substances 0.000 description 4
150000004671 saturated fatty acids Chemical class 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
229960002537 betamethasone Drugs 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
201000006747 infectious mononucleosis Diseases 0.000 description 3
229940057995 liquid paraffin Drugs 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229910000403 monosodium phosphate Inorganic materials 0.000 description 3
235000019799 monosodium phosphate Nutrition 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
239000005526 vasoconstrictor agent Substances 0.000 description 3
DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 2
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
206010047139 Vasoconstriction Diseases 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
229950009789 cetomacrogol 1000 Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 2
NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
229940075507 glyceryl monostearate Drugs 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229960004584 methylprednisolone Drugs 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
229920000056 polyoxyethylene ether Polymers 0.000 description 2
229920000166 polytrimethylene carbonate Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
150000004684 trihydrates Chemical class 0.000 description 2
230000025033 vasoconstriction Effects 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
ZUDASDOHOYYFRW-UHFFFAOYSA-N 5-chloro-2-n,2-n-dimethylquinazoline-2,4-diamine Chemical compound ClC1=CC=CC2=NC(N(C)C)=NC(N)=C21 ZUDASDOHOYYFRW-UHFFFAOYSA-N 0.000 description 1
ZHMASVAJFJFFLS-UHFFFAOYSA-N 5-chloropyridin-3-amine Chemical compound NC1=CN=CC(Cl)=C1 ZHMASVAJFJFFLS-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
241000790917 Dioxys <bee> Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
238000003657 Likelihood-ratio test Methods 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229960000735 docosanol Drugs 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229960001347 fluocinolone acetonide Drugs 0.000 description 1
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
239000012458 free base Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000012155 injection solvent Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
150000002731 mercury compounds Chemical class 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
229940012831 stearyl alcohol Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

JP49035716A 1973-04-02 1974-04-01 ベヒクル組成物 Expired JPS589081B2 (ja)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB1575873A GB1478009A (en)	1973-04-02	1973-04-02	Pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
JPS5058218A JPS5058218A (fr)	1975-05-21
JPS589081B2 true JPS589081B2 (ja)	1983-02-18

Family

ID=10064952

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP49035716A Expired JPS589081B2 (ja)	1973-04-02	1974-04-01	ベヒクル組成物

Country Status (11)

Country	Link
JP (1)	JPS589081B2 (fr)
BE (1)	BE813153A (fr)
CA (1)	CA1045974A (fr)
DE (1)	DE2347243A1 (fr)
DK (1)	DK144358C (fr)
FR (1)	FR2222998B1 (fr)
GB (1)	GB1478009A (fr)
IE (1)	IE39113B1 (fr)
LU (1)	LU69751A1 (fr)
NL (1)	NL7404378A (fr)
ZA (1)	ZA742064B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8004580L (sv) *	1980-06-19	1981-12-20	Draco Ab	Farmaceutisk beredning
KR830005852A (ko) *	1980-07-18	1983-09-14	미첼 페터 잭슨	피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법
GB2080106B (en) *	1980-07-18	1984-03-07	Weelcome Foundation Ltd	Acyclovin preparations
DE3225848A1 (de) *	1982-07-07	1984-01-19	Schering AG, 1000 Berlin und 4709 Bergkamen	Kortikoidhaltige zubereitung zur topischen applikation
US4868169A (en) *	1987-11-13	1989-09-19	E. R. Squibb & Sons, Inc.	Steroid cream formulation
LU87457A1 (fr) *	1989-02-24	1990-09-19	Oreal	Utilisation,comme composition cosmetique pour cheveux,d'une microdispersion de cire,et procede de traitement des cheveux avec une telle composition
US8491875B2 (en) *	2010-08-18	2013-07-23	Kao Corporation	Hair volumizing compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB765600A (en) *	1954-01-15	1957-01-09	Drug Houses Of Australia Ltd	Salves for veterinary use
GB903407A (en) *	1958-07-25	1962-08-15	Upjohn Co	Improvements in or relating to antibacterial antiperspirant compositions
DE1198011B (de) *	1962-08-04	1965-08-05	Iwao Kawakami	Hautpflegemittel
BR6789910D0 (pt) *	1966-10-17	1973-05-17	Fmc Corp	Processo para preparar comestiveis contendo colagenio microcristalino

1973
- 1973-04-02 GB GB1575873A patent/GB1478009A/en not_active Expired
- 1973-09-19 DE DE19732347243 patent/DE2347243A1/de active Pending
1974
- 1974-04-01 ZA ZA00742064A patent/ZA742064B/xx unknown
- 1974-04-01 NL NL7404378A patent/NL7404378A/xx unknown
- 1974-04-01 DK DK179474A patent/DK144358C/da not_active IP Right Cessation
- 1974-04-01 LU LU69751A patent/LU69751A1/xx unknown
- 1974-04-01 FR FR7411572A patent/FR2222998B1/fr not_active Expired
- 1974-04-01 BE BE142726A patent/BE813153A/fr not_active IP Right Cessation
- 1974-04-01 CA CA196,544A patent/CA1045974A/fr not_active Expired
- 1974-04-01 IE IE00703/74A patent/IE39113B1/xx unknown
- 1974-04-01 JP JP49035716A patent/JPS589081B2/ja not_active Expired

Also Published As

Publication number	Publication date
DE2347243A1 (de)	1974-10-10
LU69751A1 (fr)	1974-07-17
GB1478009A (en)	1977-06-29
AU6724674A (en)	1975-10-02
IE39113B1 (en)	1978-08-02
CA1045974A (fr)	1979-01-09
NL7404378A (fr)	1974-10-04
FR2222998A1 (fr)	1974-10-25
DK144358B (da)	1982-03-01
JPS5058218A (fr)	1975-05-21
FR2222998B1 (fr)	1977-11-04
IE39113L (en)	1974-10-02
DK144358C (da)	1984-04-09
ZA742064B (en)	1975-03-26
BE813153A (fr)	1974-10-01

Publication	Publication Date	Title
US11844836B2 (en)	2023-12-19	Topical pharmaceutical composition based on semifluorinated alkanes
US4305936A (en)	1981-12-15	Topical corticosteroid formulations
US10098894B2 (en)	2018-10-16	Transdermal cream
US4082881A (en)	1978-04-04	Topical and other type pharmaceutical formulations containing isosorbide carrier
US3924004A (en)	1975-12-02	Fatty alcohol-propylene carbonate-glycol solvent cream vehicle
KR101121529B1 (ko)	2012-02-28	스테로이드의 경시적 안정성이 개선된 외용 제제
JPS63150221A (ja)	1988-06-22	結晶性薬物含有乳化組成物
JP3731607B2 (ja)	2006-01-05	コルチコステロイドを含む油中水型ローション
CA1139665A (fr)	1983-01-18	Corticosteroide dans un excipient de sebacate
US20230037905A1 (en)	2023-02-09	Topical composition comprising tofacitinib and fingolimod
CA1182048A (fr)	1985-02-05	Compose pharmaceutique a usage local contenant des steroides anti-inflammatoires
JP2003212716A (ja)	2003-07-30	液晶型乳化組成物
GB2122087A (en)	1984-01-11	Topical corticosteroid preparation
CN118490636B (zh)	2025-07-18	本维莫德纳米乳组合物，包含其的药物制剂，及其制备方法和应用
IT9067434A1 (it)	1991-12-14	Procedimento per migliorare l'efficacia terapeutica di corticosteroidi liposolubili e composizione per l'attuazione di tale procedimento
JPS589081B2 (ja)	1983-02-18	ベヒクル組成物
JPH0676328B2 (ja)	1994-09-28	ステロイドクリ−ム製剤
JPH0676327B2 (ja)	1994-09-28	ステロイド軟膏製剤
EP2962688B1 (fr)	2020-06-24	Composition d'émulsion huile-dans-eau comportant du mométasone et du propylen glycol
JP2009114081A (ja)	2009-05-28	Ｏ／ｗ乳化型皮膚外用組成物
JP3174590B2 (ja)	2001-06-11	ステロイド軟膏剤
JPH0140803B2 (fr)	1989-08-31
JP2015193626A (ja)	2015-11-05	水中油乳化剤形の医薬組成物及びその製造方法
JP2001233772A (ja)	2001-08-28	外用剤組成物
US12447161B2 (en)	2025-10-21	Topical pharmaceutical formulation